BR112018001391A2 - terapias de combinação - Google Patents

terapias de combinação

Info

Publication number
BR112018001391A2
BR112018001391A2 BR112018001391A BR112018001391A BR112018001391A2 BR 112018001391 A2 BR112018001391 A2 BR 112018001391A2 BR 112018001391 A BR112018001391 A BR 112018001391A BR 112018001391 A BR112018001391 A BR 112018001391A BR 112018001391 A2 BR112018001391 A2 BR 112018001391A2
Authority
BR
Brazil
Prior art keywords
combination therapies
polypeptide
compositions
treating
subject
Prior art date
Application number
BR112018001391A
Other languages
English (en)
Inventor
Scheving Reynir
Guðmundsdóttir Ágústa
Original Assignee
Enzymatica Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzymatica Ab filed Critical Enzymatica Ab
Publication of BR112018001391A2 publication Critical patent/BR112018001391A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

a invenção fornece uma terapia de combinação para uso em tratamento de um biofilme bacteriano em um sujeito que compreende (a) um polipeptídeo que tem atividade de protease de serina e (b) um ou mais compostos de antibiótico. além disso, são fornecidos composições e métodos de uso das mesmas.
BR112018001391A 2015-07-24 2016-07-22 terapias de combinação BR112018001391A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15178209.1A EP3120866A1 (en) 2015-07-24 2015-07-24 Use of marine serine proteases for removal, prevention and inhibition of formation and growth of biofilms
PCT/EP2016/067570 WO2017017027A1 (en) 2015-07-24 2016-07-22 Combination therapies

Publications (1)

Publication Number Publication Date
BR112018001391A2 true BR112018001391A2 (pt) 2018-09-11

Family

ID=53785469

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001391A BR112018001391A2 (pt) 2015-07-24 2016-07-22 terapias de combinação

Country Status (12)

Country Link
US (1) US11338021B2 (pt)
EP (2) EP3120866A1 (pt)
JP (1) JP2018521143A (pt)
KR (1) KR20180031704A (pt)
CN (1) CN107921102B (pt)
AU (1) AU2016301021B2 (pt)
BR (1) BR112018001391A2 (pt)
CA (1) CA2992677A1 (pt)
DK (1) DK180380B1 (pt)
MX (1) MX2018000984A (pt)
RU (1) RU2725800C2 (pt)
WO (1) WO2017017027A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201701315D0 (en) 2017-01-26 2017-03-15 Enzymatica Ab Novel treatments
WO2020229521A1 (en) * 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for inhibiting or reducing bacterial biofilms on a surface
US20230165776A1 (en) * 2020-05-13 2023-06-01 Zymiq Technology Ab Protease formulation for treatment of microbial infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US20020037260A1 (en) * 1997-10-16 2002-03-28 Budny John A. Compositions for treating biofilm
EP1202743B1 (en) 1999-06-18 2004-10-06 Jon Bragi Bjarnason Pharmaceutical and cosmetic compositions comprising cod serine proteases and their pharmaceutical and cosmetic use
GB0205593D0 (en) * 2002-03-09 2002-04-24 Univ Nottingham Treatment of surfaces populated by bacteria
CA2780756A1 (en) 2009-11-23 2011-05-26 Prothera, Inc. Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
CN104039812A (zh) 2011-05-31 2014-09-10 和黄生物膜医疗解决方案有限公司 细胞聚集体的分散和脱离
CN103007258A (zh) 2011-09-22 2013-04-03 安淇生物控释技术(苏州)有限公司 含鱼丝氨酸蛋白酶和抗菌化合物的医用组合物及其用途
WO2013095439A1 (en) * 2011-12-21 2013-06-27 Colgate-Palmolive Company Oral care compositions
CN103191491A (zh) 2012-01-10 2013-07-10 查红梅 一种包装物及其用途和制法
RU2646102C2 (ru) 2012-05-09 2018-03-01 Контрафект Корпорейшн Предотвращение, разрушение и обработка биопленки лизином бактериофага
KR20150013280A (ko) 2012-05-11 2015-02-04 스미스 앤드 네퓨, 인크. 박테리아 균막을 제거하기 위한 세아프로제의 용도
CN203090136U (zh) * 2013-02-02 2013-07-31 成都玺汇科技有限公司 一种口鼻两用喷雾器
GB201405784D0 (en) * 2014-03-31 2014-05-14 Enzymatica Ab Novel methods, polypeptides and uses thereof
US20160339087A1 (en) * 2014-01-29 2016-11-24 Enzymatica Ab Novel treatments

Also Published As

Publication number Publication date
EP3325002A1 (en) 2018-05-30
RU2725800C2 (ru) 2020-07-06
WO2017017027A1 (en) 2017-02-02
CA2992677A1 (en) 2017-02-02
DK201870043A1 (en) 2018-02-05
RU2018106490A3 (pt) 2020-01-24
CN107921102A (zh) 2018-04-17
KR20180031704A (ko) 2018-03-28
JP2018521143A (ja) 2018-08-02
US20200085921A1 (en) 2020-03-19
AU2016301021A1 (en) 2018-02-01
AU2016301021B2 (en) 2022-11-10
DK180380B1 (en) 2021-03-17
US11338021B2 (en) 2022-05-24
MX2018000984A (es) 2018-08-09
CN107921102B (zh) 2022-09-09
EP3120866A1 (en) 2017-01-25
RU2018106490A (ru) 2019-08-26

Similar Documents

Publication Publication Date Title
MD3209310T2 (ro) Compoziții care conțin tulpini bacteriene
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
MX2022004304A (es) Agentes inductores de apoptosis.
CA2956871C (en) Compounds active towards bromodomains
MD3240554T2 (ro) Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune
MD3307288T2 (ro) Compoziții care conțin tulpini bacteriene
MD3204024T2 (ro) Compoziții care conțin tulpini bacteriene
BR112017006664A2 (pt) terapias de combinação
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
PH12019501097A1 (en) Magl inhibitors
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
PH12019501102A1 (en) Magl inhibitors
BR112015023207A2 (pt) uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
PH12017501864A1 (en) Compositions and methods for treating autism
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2018003301A (es) Inhibidores de pcna.
BR112018001391A2 (pt) terapias de combinação
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
MX2020000402A (es) Nuevos derivados de xantina sustituidos.
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
BR112017004552A2 (pt) composições farmacêuticas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]